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Tumour hypoxia is a common clinical phenomenon that is
believed to predispose to failure of treatments with radiotherapy
and some chemotherapy (Gatenby et al, 1991; Hockel et al, 1993;
Okunieff et al, 1993; Teicher, 1994; Nordsmark et al, 1996). This
unique biochemistry of the tumour microenvironment can be
exploited for therapeutic gain – through the reductive activation of
prodrugs under low oxygen tension. Bioreductive drugs are selec-
tively metabolized in tissues that experience low oxygen tensions,
yielding products that are substantially more cytotoxic than their
parent compounds (Adams and Stratford, 1986, 1994; Stratford
and Stephens, 1989).
Tirapazamine (TPZ, 3-amino-1,2,4-benzotriazine 1,4-di-N-
oxide, SR4233, WIN 59075) is the lead compound in a series of
potent cytotoxins that selectively kill hypoxic rodent and human
tumour cells both in vitro and in vivo (Zeman et al, 1986; Durand,
1994; Kim and Brown, 1994). Unlike other classes of bioreductive
agents that can require severe radiobiological hypoxia (≤ 0.3%
pO2) to generate significant differential cytotoxicities (e.g.
quinones and nitro(hetero)arenes), TPZ toxicity appears to extend
over a broader range of ‘intermediate’ oxygen concentrations. This
ensures that a greater proportion of a heterogeneous tumour cell
population is effectively targeted during treatment, particularly
since this ‘intermediate’ hypoxic environment is considered to
dominate in determining response to radiotherapy (Brown, 1993;
Koch, 1993; Wouters and Brown, 1997).
Preclinical studies have demonstrated the efficacy of using TPZ
in combination with both fractionated radiotherapy (Brown and
Lemmon, 1990, 1991) and chemotherapeutic agents (Dorie and
Brown, 1993), and TPZ is currently in phase II clinical trials for
use in combination with fractionated radiotherapy, and phase III
trials in combination with cisplatin chemotherapy. A recently
completed phase III study of TPZ combined with cisplatin for
stage IIIB and IV non-small-cell lung cancer (NSCLC) has shown
a doubling of overall response rates (17% to 27%) and a signifi-
cant survival advantage compared to cisplatin alone (Von Pawel
and Von Roemeling, 1998).
Previous studies on the metabolism of tirapazamine using
mouse liver microsomes (Walton et al, 1989, 1992) and tumour
cell lines (Cahill and White, 1990; Wang et al, 1993) have demon-
strated that both cytochrome P450 and NADPH:cytochrome P450
reductase (P450R) contribute to the overall reduction of TPZ to its
two-electron reduced product SR4317. EPR spectroscopic studies
utilizing rat liver microsomes identified P450R as the major
hepatic microsomal enzyme responsible for the reductive activa-
tion of TPZ to the one-electron nitroxide radical intermediate
(Lloyd et al, 1991), which is believed to be cytotoxic in its proto-
nated form (Costa et al, 1989; Wang et al, 1992; Brown, 1993).
While the role of cytochrome P450 in the one-electron activation
of TPZ is unclear (Patterson et al, 1998), P450R has been directly
implicated in a number of studies (Silva and O’Brien, 1993;
Patterson et al, 1995, 1997). Further, the rate of metabolism has
been linked to cytotoxicity under hypoxic conditions in some but
not all studies (Biedermann et al, 1991). Moreover, TPZ is reduced
in purified rat liver P450R (Walton et al, 1989; Cahill and White,
1990) leading to production of strand breaks in co-incubated
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Correspondence to: EC Chinjeplasmid DNA (Fitzsimmons et al, 1994). In a panel of human
breast cancer cell lines, expression of P450 reductase has been
correlated with both hypoxic toxicity and metabolism of TPZ
(Patterson et al, 1995). This relationship was subsequently
substantiated by transecting and stably overexpressing human
P450R cDNA in the human breast cell line, MDA 231 (Patterson
et al, 1997). These results unequivocally demonstrated that P450R
was an important determinant of the oxic and hypoxic toxicity of
TPZ in breast tumour cell lines, being consistent with the one-
electron reduction of TPZ by this flavoenzyme.
Two recent studies using the lung adenocarcinoma cell line,
A549 (Elwell et al, 1997; Evans et al, 1998) have, however, raised
apparent uncertainties over the role of P450R in TPZ metabolism
and toxicity. Elwell and colleagues (1997) adapted the A549 cell
line to escalating doses of TPZ under aerobic conditions and
characterized the changes associated with drug resistance. A large
decrease in P450R activity was found which was not reflected in
the loss of hypoxic metabolism or cytotoxicity in the adapted cell
lines. Meanwhile, Evans and colleagues (1998) measured both
DNA damage and TPZ metabolism in isolated nuclei from the
A549 cells and demonstrated that essentially all the DNA damage
produced by TPZ under hypoxia could be accounted for by
intranuclear metabolism. Their findings led them to believe that
the intranuclear enzyme(s) implicated in TPZ-mediated toxicity
was not P450R.
Thus, while it is clearly demonstrated that P450R is important in
the metabolism and toxicity of TPZ in breast cancer cells, it is
important to establish the generality of this contention in the light
of the findings of Elwell et al (1997) and Evans et al (1998) using
A549 lung cancer cells. Therefore, we report here a study of the
role of P450R in the metabolism and cytotoxicity of TPZ in a
panel of NSCLC cell lines. In addition, we relate our findings on
TPZ sensitivity in these lung lines with our previously published
results on the TPZ sensitivity in breast cancer cells (Patterson et al,
1995) and with the sensitivity of all these cell types to other
unrelated cancer chemotherapeutic agents (Houlbrook et al, 1994).
MATERIALS AND METHODS
Chemicals
Tirapazamine, SR4317 and SR4330 were synthesized in house
using previously described methods (Seng and Ley, 1972).
NADPH was purchased from Boehringer Mannheim (Lewes,
UK), high-performance liquid chromatography (HPLC)-grade
methanol was purchased from Merck (Lutherworth, UK). All
other reagents were of analytical grade and were purchased from
Sigma (Poole, UK). Tissue culture medium was obtained from
Gibco-BRL and fetal calf serum (FCS) from Sigma.
Cells and culture
Table 1 lists the seven human lung cell lines used in this work.
These were obtained from the National Cancer Institute (NCI)
panel. All cell lines were maintained in exponential growth phase
in RPMI-1640 medium, supplemented with 2 mM glutamine and
10% (v/v) FCS.
Preparation of cell lysates
Cells in exponential growth phase were washed twice with phos-
phate-buffered saline (PBS) and harvested using trypsin–EDTA.
Following centrifugation at 100 g for 8 min (4°C), pellets were
taken and washed in ice-cold hypotonic nuclear buffer A (10 mM
HEPES/potassium hydroxide pH 7.4, 1.5 mM magnesium
chloride, 10 mM potassium chloride, 0.05 mM dithiothreitol). After
repelleting, cells were suspended in 1.0 ml of nuclear buffer A and
allowed to stand for 10 min at 4°C. Suspensions were sonicated
using a MSE Soniprep 150 for 3 ´ 5 s at a nominal frequency of
23 kHz and an oscillation amplitude of between 5 and 10 mm.
Samples were placed on ice between each sonication. The suspen-
sions were allowed to stand in ice for further 10 min and then
centrifuged at 7800 g for 15 min at 4°C. The resulting lysate was
removed and stored at –80°C until required. The protein concen-
tration of the cell lysates was determined using the Pierce protein
assay (Smith et al, 1985) using high-grade bovine serum albumin
(BSA) as the standard.
NADPH:cytochrome P450 reductase activity
NADPH:cytochrome P450 reductase activity was determined
spectrophotometrically as the NADPH-dependent reduction of
cytochrome c. Each incubation comprised 400 ml of the
cytochrome c (final concentration 50 mM), 100 ml of 10 mM potas-
sium cyanide (final concentration 1 mM) and 10–300 mg lysate
protein (10–100 ml volume) made up to 0.98 ml with 100 mM
phosphate buffer, pH 7.6. The reaction was equilibrated to 37°C
and was initiated by addition of 20 ml of 10 mM NADPH to the test
cuvette (final concentration 200 mM), and the rate of reduction of
cytochrome c was monitored at 550 nm for 3 min against a blank
without NADPH. Initial rates of reaction were based on an extinc-
tion coefficient of 21 mM–1 cm–1 calculated (Williams and Kamin,
1962) and expressed as nmol cytochrome c reduced min–1 mg–1 of
cell lysate protein.
Metabolism of tirapazamine by cell lysates
Incubations were carried out in air or under nitrogen at 37°C in
4-ml amber glass vials (Chromacol, Welwyn Garden City, UK)
sealed with Subaseal (Aldrich, Gillingham, UK). The 500-ml incu-
bation volume comprised 100 ml of cell lysate (maximum final
protein concentration of 1.5 mg ml–1), 100 ml of NADPH (5 mM
dissolved in incubation buffer, giving a final incubation concentra-
tion of 1 mM), 20 ml of tirapazamine (50 mM dissolved in DMSO
to give a final incubation concentration of 2 mM) and 280 ml of
incubation buffer (0.2 M phosphate buffer, pH 7.4). After pre-
incubation under nitrogen for 10 min, the reaction was started by
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Table 1 NADPH:cytochrome P450 reductase activity and SR 4233
metabolism in a panel of NSCLC cell lines
Cell line Characteristics NADPH:cyt. P450 SR 4317 formation
reductase (± s.d.) rate (± s.d.)
(nmol cyt. c min–1 mg–1) (nmol min–1 mg–1)
NCI-A549 Adenocarcinoma 22.0 ± 2.7 17.32 ± 3.01
NCI-H322 Bronchio-alveolar 18.4 ± 3.2 17.67 ± 1.38
NCI-H358 Bronchio-alveolar 17.7 ± 1.0 17.68 ± 2.01
NCI-H460 Large-cell carcinoma 17.6 ± 2.3 18.92 ± 3.62
NCI-H522 Adenocarcinoma 15.4 ± 2.2 13.26 ± 0.86
NCI-H647 Adenosquamous 9.1 ± 1.0 8.47 ± 1.0
NCI-H226 Squamous carcinoma 7.3 ± 1.0 6.57 ± 0.80addition of tirapazamine (maintained under nitrogen) using a
Hamilton syringe inserted through the Subaseal. Reactions were
stopped after 40 min by transferring 2 ´ 200 ml aliquots of the
incubate into polypropylene vials containing 50 ml of internal
standard [4-nitroquinoline N-oxide; 0.4 mg ml–1 in 20% (v/v)
ethanol] and 400 ml of methanol. Samples were vortexed vigor-
ously for 2 min, centrifuged for 5 min at 3000 rpm and 150 ml
aliquots of the supernatants were injected onto the HPLC system
for analysis. At least three lysate preparations for each cell line
were incubated, each in duplicate, with duplicate analyses.
Formation of SR4317 was linear for at least 40 min and up to a
protein concentration of 1.5 mg ml–1.
Concentrations of SR4317 in incubation samples were deter-
mined by isocratic reverse phase HPLC (Walton and Workman,
1990). Chromatography was performed using a waters mBondapak
phenyl 4-mm radial compression cartridge in a Waters radial
compression module (Waters Chromatography, Watford, UK) and
protected with a phenyl guard column consisting of similar
packing material. The mobile phase consisted of 32% methanol
(v/v) in water delivered at a flow rate of 3 ml min–1. Detection was
at 267 nm. Approximate retention times under these conditions
were 2.7, 4.6, 5.2 and 8.4 min for tirapazamine, SR4330, SR4317
and 4-nitroquinoline N-oxide (internal standard) respectively.
Concentrations of metabolites were calculated from peak height
ratios and comparison with calibration curves (0–500 mM)
prepared by spiking inactivated lysate preparations with known
amounts of metabolite.
Drug sensitivity
Dose–response curves were determined using the (3-(4-5-
dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
proliferation assay, which is based on the ability of viable cells to
convert a soluble tetrazolium salt, MTT, into purple formazan
crystals (Mossman, 1983). The optical density of the dissolved
crystals is proportional to the number of viable cells, although this
varies between cell lines as the conversion of MTT to formazan
depends on the level of mitochondrial dehydrogenase activity in
each cell line (Carmichael et al, 1987). The conditions for carrying
out the assay have been described elsewhere (Carmichael et al,
1987; Robertson et al, 1994) and require plating 1 ´ 103–5 ´ 103
cells (depending on cell line) into each well of a 24-well glass dish
3 h before exposure to tirapazamine for 3 h at 37°C in either air or
hypoxia. The cells were then washed free of drug and allowed to
grow for 4 days in 0.4 ml of fresh medium. After 4 days, MTT was
added (0.2 mg ml–1 medium) and cells were incubated for further
4 h. Culture medium and unconverted MTT were removed and the
formazan crystals dissolved in 0.2 ml DMSO. An aliquot of 25 ml
of glycine buffer, pH 10.5 (Plumb et al, 1989) was then added and
the optical density at 540 nm measured on a multiwell spectropho-
tometer. Values of IC50, the concentration of tirapazamine required
to reduce the optical density by 50% compared with the untreated
controls, were used as the measure of cellular sensitivity to a given
treatment. The IC50 values quoted are the means of at least three
independent experiments conducted on different days.
Statistical analysis
The data were analysed using the standard model for a linear func-
tional relationship with sampling errors in both variables. The data
were logarithmically transformed and the pooled variance of each
data set was calculated. It is assumed that the random sampling
errors are normally and independently distributed with zero means
and variances inversely proportional to the sample size. For statis-
tical analysis of any two data sets, the model is fitted to the obser-
vations by the method of weighted least squares, each sample
mean being weighted in direct proportion to the sample size. The
statistical goodness-of-fit for any two data sets was tested by
calculating the weighted mean-square deviation of the observa-
tions for mean xn and mean yn from the fitted model, and
comparing this mean-square with the pooled variance within
samples by a variance-ratio test. The statistical significance of the
estimate of the slope of the straight line of best fit was tested by a
Student’s t-test. Tests for correlation were carried out by fitting
linear functional relationship on a log-log plot, and the signifi-
cance of the slope was tested by a Student’s t-test.
RESULTS
Enzyme profiling and metabolism of tirapazamine
P450R activity was measured in cell lysates from the panel of
seven human lung cancer cell lines (Table 1) and covered a
TPZ: metabolism and toxicity in lung cancer cell lines 1129
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Figure 1 A plot showing dependence on NADPH:cytochrome c (P450)
reductase activity of the rate of conversion of tirapazamine under hypoxia to
SR 4317 by cell lysates of the lung cancer cell lines. Bars indicate standard
errors of the mean
Table 2 Response to tirapazamine under aerobic and hypoxic conditions by
NSCLC panel
Cell line Tirapazamine Differential
(IC50 mM + s.d.) toxicitya
3-h Aerobic 3-h Hypoxic
exposure exposure
A549 247.0 ± 44 7.4 ± 0.5 33.2
H322 980.0 ± 24 54.3 ± 1.7 18.1
H358 1231.0 ± 62 48.1 ± 5.6 25.6
H460 110.0 ± 10 4.2 ± 2.0 26.2
H522 141.0 ± 12 8.9 ± 0.6 15.8
H647 135.0 ± 22 6.3 ± 2.0 21.4
H226 941.0 ± 189 22.8 ± 4.6 41.3
aRatio of 3-h IC50 values of air/nitrogen.threefold range. Table 1 includes data on the formation velocity of
its two-electron reduced product SR 4317 when cell lysates were
incubated with TPZ under nitrogen and in the presence of NADPH
as co-factor. A plot of P450R activity versus rate of SR 4317
formation by cell lysates of each cell line, with NADPH as elec-
tron source, is shown in Figure 1. Clearly a strong correlation
exists between P450R activity and SR 4317 formation, with higher
values of enzyme activity resulting in greater rates of metabolism
(slope = 1.03 ± 0.09; P < 10–15). When similar experiments were
carried out in air, no metabolism was detected.
Drug sensitivity
The toxic effect of tirapazamine on the cell lines was determined
by exposing cells to the drug for 3 h under aerobic and hypoxic
conditions. Cytotoxicity was measured by the MTT proliferation
assay and data obtained is summarized in Table 2. Also included
in the Table are values of differential toxicity. Each cell shows
increased sensitivity to TPZ under hypoxia, with values of
differential toxicity ranging from 15 to 41. The potential role
of intracellular P450 reductase activity in the toxicity of TPZ
across the lung line panel was assessed by examining the interrela-
tionship between rate of NADPH-dependent cytochrome c reduc-
tion and IC50 under acute (3-h) aerobic and hypoxic exposures. A
plot showing such a dependence of IC50 on P450R is presented in
Figure 2. However, intracellular enzyme activity did not predict
cytotoxicity under either aerobic (slope = –0.04 ± 0.17, P = 0.80)
or hypoxic (slope = –0.06 ± 0.17, P = 0.73) exposure condition.
Similarly, the data obtained in the present study suggest no
obvious relationship between the rate at which cell lysates,
obtained from the panel of lung cell lines reduced TPZ under
hypoxia to SR 4317 and the IC50 values (Figure 3).
In order to provide insights regarding the basis for this differ-
ence in TPZ toxicity between the lung lines and our previously
published work on breast cancer cell lines (Patterson et al, 1995,
1997), we have compared the sensitivity of the lung and breast cell
lines to a wide range of (unrelated) chemotherapeutic agents
(Houlbrook et al, 1994). This latter data showed wide variations in
IC50 values for all the drugs tested, possibly reflecting the diverse
range of histological cell types represented within this panel.
Indeed for many chemotherapeutic agents, greater than tenfold
variability in sensitivity was observed between the cell lines.
Compare-analysis of acute (3-h) aerobic and hypoxic TPZ
sensitivity to each of the other agents in the breast and lung cancer
cell lines is presented in Table 3. The panel of lung cancer cell
lines showed significant correlation between sensitivity to TPZ
and each of the members of the panel of chemotherapeutic agents.
In contrast, no correlation was observed between any of the
chemotherapeutic agents in the panel of human breast cancer cell
lines. These results demonstrate the major inherent differences
between the panel of lung and breast cell lines (Patterson et al,
1995) with respect to the response to diverse cytotoxic drugs.
DISCUSSION
The cytotoxicity of TPZ is thought to arise as a consequence of
activation by reductive enzymes that donate single electrons to the
1130 EC Chinje et al
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Figure 2 Relationship between IC50 values, derived by MTT assay of
human non-small-cell lung cancer cell lines exposed to tirapazamine for 3-h
under hypoxic (l) or aerobic (l l) conditions and NADPH:cytochrome c
(P450) reductase activity. Bars indicate standard errors of the mean
Figure 3 Relationship between rate of conversion of tirapazamine under
hypoxic conditions to SR 4317 and the IC50 values for 3-h hypoxic exposure.
Bars indicate standard errors of the mean
Table 3 Correlations between sensitivity to SR 4233 and other unrelated
chemotherapeutic agents in human cancer cell lines*a
Drugs Tirapazamine exposure
3-h Aerobic 3-h Hypoxic
Breast cancer cell lines
Adriamycin t4 = –1.23 (P = 0.29) t4 = 0.52  (P = 0.63)
m-AMSA t4 = –0.47 (P = 0.67) t4 = 0.15  (P = 0.89)
Chlorambucil t4 = 0.08 (P = 0.94) t4 = 0.31  (P = 0.77)
Melphalan t4 = 1.11 (P = 0.33) t4 = 1.05  (P = 0.35)
Etoposide (VP-16) t4 = 0.33 (P = 0.76) t4 = 0.45 (P = 0.67)
BCNU t4 = 3.35 (P = 0.03) t4 = 1.52  (P = 0.20)
Cisplatin t4 = 1.42 (P = 0.25) t4 = 1.66  (P = 0.17)
Mitoxantrone t4 = 0.93 (P = 0.41) t4 = 1.30  (P = 0.26)
Lung cancer cell lines
Adriamycin t5 = 12.98 (P = 00005) t5 = 7.60 (P = 0.00063)
m-AMSA t5 = 2.44 (P = 0.59) t5 = 3.42 (P = 0.019)
Chlorambucil t5 = 8.69 (P = 0.0003) t5 = 13.65 (P = 0.00004)
Melphalan t5 = 2.44 (P = 0.038) t5 = 6.62  (P = 0.0012)
Etoposide (VP-16) t5 = 3.50 (P = 0.017) t5 = 4.68 (P = 0.0054)
BCNU t5 = 2.62 (P = 0.047) t5 = 3.17 (P = 0.025)
Cisplatin t5 = 4.55 (P = 0.0061) t5 = 4.99  (P = 0.0041)
Mitoxantrone t5 = 3.01 (P = 0.03) t5 = 3.95  (P = 0.011)
aOn 5 degrees of freedom, to > 2.57 for 5% level of significance.parent drug to produce radical species that cause DNA single-
strand breaks (SSBs), double-strand breaks (DSBs) and, ulti-
mately, chromosome aberrations (Brown, 1993). The present
investigation examined the role of the flavoenzyme P450R in the
hypoxic metabolism of TPZ across a panel of lung cancer cell line
lysates. The data clearly demonstrated that intracellular P450R
activity correlates strongly with the rate of formation of SR 4317,
an indirect measure of radical formation (P < 10–15). This observa-
tion is consistent with earlier reports where a good correlation was
found between P450R activity and SR 4317 formation velocity 
(P = 0.009) in a panel of six human breast cancer cell lines in vitro
(Patterson et al, 1995). This was unequivocally substantiated in
subsequent stable expression studies with human P450R cDNA
(Patterson et al, 1997). In agreement, numerous metabolism
studies have implicated P450R in the reduction of TPZ to SR 4317
(Cahill and White, 1990; Walton and Workman, 1990; Riley and
Workman, 1992; Walton et al, 1992; Riley et al, 1993; Silva and
O’Brien, 1993). It has been suggested that fundamental differences
might exist between the enzymology of human breast and lung
cancer cell lines in vitro (Simm et al, 1996; Brown and Wang,
1998). However, the collective evidence would strongly suggest
that the principle flavoenzyme involved in the reduction of TPZ in
human cancer cell lines in vitro is P450R.
Although a strong correlation is apparent between P450R
activity and SR4317 formation in the lung cell lines, cytotoxicity
was apparently independent of each of these parameters,
suggesting that some other factor(s) must be playing a dominant
role with respect to the overall toxicity in the lung lines.
Preliminary data reported elsewhere (Barham et al, 1995) and
confirmed in the present studies, suggest no obvious relationship
between IC50 and the rate at which cell lysates obtained from the
panel of lung cell lines reduced TPZ under hypoxia to SR 4317.
This contrasts the earlier observations across the panel of human
breast cancer cell lines (Patterson et al, 1995) where P450R was
clearly involved in the hypoxic metabolism and cytotoxicity of
TPZ.
The close relationship between TPZ activation and cytotoxicity
in the panel of breast cancer cell lines derived from tumours of
similar histological type suggested that a major determinant of
cytotoxicity was the accumulation of TPZ-mediated DNA damage
arising from P450R-dependent metabolism (Patterson et al, 1995).
In contrast, the lung lines, derived from a broad range of histo-
logical subtypes, show no dependence on P450R-mediated TPZ
metabolism and cytotoxicity. It is likely that this is due to the
intrinsic capacity to recognize, repair and/or tolerate TPZ-medi-
ated DNA damage which underlies the responses among the lung
cell lines. It is pertinent that this distinction in chemoresponsive-
ness between the two panels of lung and breast cancer cell lines
used has been reported from our laboratory for a spectrum of
unrelated chemotherapeutic agents (Houlbrook et al, 1994). We
demonstrated that the range of sensitivity for each drug tended to
be greater across the lung cancer cell lines and that cross-
sensitivity to these agents was common (Kendall’s coefficient of
concordance 0.69, P = 0.0001). The strong correlations between
sensitivity to TPZ exposure and other unrelated chemotherapeutic
agents in the lung lines but not the breast lines (Table 3) suggests
that intrinsic differences may exist between the lung and breast
cell lines in vitro. Indeed, the nature of the DNA damage induced
by these chemotherapeutic agents is diverse, and includes inter-
calation, intra- and inter-strand cross-links and single and double
strand-breaks, which implies a flexible response to multiple forms
of DNA damage in some of the lung cell lines. Whereas TPZ
sensitivity under aerobic or hypoxic exposure conditions corre-
lated with every other drug used across the panel of lung cell lines,
no relationships were apparent for any of the agents with the breast
cell lines. This is consistent with the hypothesis which we propose
to test, that P450R dominates response to TPZ in the breast cell
lines, whereas in the NSCLC lines it is apparently their inherent
sensitivity that is likely to dominate and dictate the outcome of
TPZ exposure.
The role of P450R in the bioactivation of TPZ has been brought
into question (Elwell et al, 1997; Evans et al, 1998). Elwell et al
(1997) adapted the A549 human lung adenocarcinoma cell line to
TPZ under chronic aerobic exposure condition in order to eluci-
date the mechanism(s) of aerobic toxicity. Their results showed
that the adapted cell lines expressed extremely low levels of
P450R activity (1–3% of the parental activity) but apparently only
aerobic toxicity was significantly modified (9.6-fold). Hypoxic
toxicity was only marginally modified (1.5-fold), which did not
reflect the reduced enzyme expression. In questioning this rela-
tionship, we restored P450R activity in one of the TPZ-resistant
clones by stable transfection (Chinje et al, 1998; Saunders et al,
1999). This significantly increased both hypoxic and aerobic
sensitivities and restored metabolism so that it resembled that of
the original parental line. Thus, P450R clearly contributes to both
oxic and hypoxic TPZ-mediated toxicity although other flavo-
enzymes may participate in TPZ reduction (reviewed in Patterson
et al, 1998).
Support for other enzyme(s) involved in TPZ activation comes
from studies carried out on the role of intranuclear metabolism
(Evans et al, 1998). These workers examined the co-factor require-
ments for TPZ metabolism leading to SSBs in isolated nuclei from
A549 cells and demonstrated that DNA damage induction by TPZ
had an absolute requirement for either NADPH or NADH in the
nuclei. However, it was concluded from their experiments, by
adding both co-factors simultaneously, that the effect was not the
result of two separate enzymes with either co-factor requirement,
but rather the result of an enzyme(s) capable of utilizing both co-
factors as reducing equivalents. We also examined the co-factor
requirements for TPZ metabolism by cell lysates derived from
A549, as well as the other six from within the panel, and arrived at
a similar conclusion, although NADPH supported the majority
(60–90%) of the metabolism (data not shown). It is of clinical rele-
vance to determine which other enzyme(s) may be involved in the
metabolism and activation of this lead bioreductive agent.
The suggestion that other enzyme(s) requiring NADPH and/or
NADH may be involved in TPZ metabolism will almost certainly
place additional demands on the reducing-equivalents pool. The
regulation of the pathway for producing these reducing equivalents
is a critical control point since drug sensitivity as well as the ability
to respond to DNA damage can be affected by their supply. NADH
is formed during glycolysis following the conversion of glucose-
6-phosphate to pyruvate, and NADPH is generated via the hexose
monophosphate shunt (HMS) pathway. The HMS is an important
biochemical pathway involved in DNA, steroid and lipid biosyn-
thesis and in maintenance of GSH/GSSG and NAD(P)H/NAD(P)+
redox equilibra. Given that the ‘resting’ pool size of GSH in most
cell types is several-fold greater than that of NADPH, the GSH
pool can serve as a redox buffer, replenishing NADPH via the
reverse of the glutathione reductase reaction following drug expo-
sure (Biaglow et al, 1977). There is also evidence to suggest that
hypoxia may result in the pyridine nucleotide redox state tilting in
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(Jones, 1991; Arteel et al, 1998). There are reports on the stimula-
tion of the HMS pathway in mammalian cells (including A549 cells)
following incubations with a number of nitroheterocyclics (Varnes
et al, 1984). In agreement with the above findings, it was observed
that the increased demand for NADPH as a consequence of several-
fold increases in P450R activity in the human breast cell lines
MDA231 (Patterson et al, 1997), the lung line A549 (Chinje et al,
1998; Saunders et al, 1999) and in P450R-transfected T47D and
HT1080 cells (AV Patterson et al, unpublished data), did not limit
the sensitivity to TPZ exposure. For instance, in our published data
on the breast cell lines, the changes in P450R were only sixfold and
this resulted in approximately sixfold change in sensitivity
(Patterson et al, 1995). Further, when P450R is overexpressed by
50-fold in the MDA231 breast cell line (Patterson et al, 1997), a
tight correlation is sustained between P450R activity and cytotoxi-
city of TPZ. This strongly suggests that reducing equivalents are not
rate limiting even at very high levels of P450R activity.
In conclusion, we have demonstrated that P450R plays a signifi-
cant role in the activation of TPZ in a panel of lung cancer cell
lines. However, in contrast to the panel of breast cancer cell lines
where hypoxic metabolism of TPZ correlates with toxicity; in the
lung lines, it is our hypothesis that the ability of these cells to
respond to DNA damage may underly the ultimate expression of
toxicity. Should this be the case, it would raise concerns over the
use of the alkaline comet assay as a surrogate measure of response
to TPZ in vivo (Siim et al, 1996). There is more to learn of the
enzyme(s) involved in drug activation and the relevance of sub-
cellular location, that could ultimately allow the identification and
rational selection of patients who are likely to respond to TPZ
therapy.
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